Xultophy approved for renal impairment
Richard Thomas,
1 Min
Clinical
Xultophy approved for renal impairment
Richard Thomas,
1 Min
In Clinical
Let’s get clinical. Follow the links below to find out more about the latest clinical insight in community pharmacy.
Bookmark
Record learning outcomes
The European Commission recently approved Xultophy (insulin degludec plus liraglutide) for adults with type 2 diabetes and moderate renal impairment (creatinine clearance 30-59ml/min). Up to 40 per cent of people with type 2 diabetes develop some degree of renal impairment.
Copy Link
Record my learning outcomes
Save for later
Clinical
Let’s get clinical. Follow the links below to find out more about the latest clinical insight in community pharmacy.
In Clinical
Let’s get clinical. Follow the links below to find out more about the latest clinical insight in community pharmacy.